Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3229-3234

  Garzetti, G Gioele ^a   Ciavattini, Andrea ^a   Provinciali, Mauro ^b   Di Stefano, Giuseppina ^b   Lucarini, Guendalina ^a   Goteri, Gaia ^a   Biagini, Graziella ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

Apoptosis; Cervical carcinoma; Chemosensitivity; Combination chemotherapy; Neoadjuvant chemotherapy; p53 immunostaining; p53 protein

Indexed keywords

BLEOMYCIN; CISPLATIN; DNA; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR CELL; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0029799803     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Stratton MR: The p53 gene in human cancer. Eur J cancer 28: 293-295, 1992.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
3. Lamb P, Crawford L: Characterization of the human p53 gene. Mol Cell Biol 6: 1379-85, 1986.
4. Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
5. Crook T, Wrede D, Vousden KH. p53 point mutations in HPV negative human cervical carcinoma cell lines. Oncogene 6: 873-875, 1991.
6. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
7. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
8. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291, 1994
9. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
10. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman RE, Jack T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
11. Watell E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I. Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157, 1994.
12. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39-47, 1994.
13. Makris A, Powles TJ, Dowsett M, et al: p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1181, 1995.
14. Mathieu MC, Koscilny S, Le Bihan ML, Spielmann M, Arriagada R: p53 protein expression and chemosensitivity in breast cancer. Lancet 345: 1182, 1995.
15. Piver MS, Rutledge, F and Smith JP: Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44: 265-272, 1974.
16. World Health Organization, WHO handbook for reporting results of cancer treatment, Geneva. World Health Organization 48: 16-21, 1979.
17. Fried J, Perz AG, Clarkson BD: Rapid hypotonic method for flow cytofluorimetry of monolayer cell cultures. J Histochem Cytochem 26: 921-923, 1978.
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279, 1991.
19. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Romanini C, Biagini G: Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. Eur J Obstet Gynecol Biol Reprod 63: 31-36, 1995.
20. Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumors. Am J Pathol 140: 145-153, 1992.
21. Bartek J, Bartkova S, Vojtesk B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common features of a wilde spectrum of human malignancies. Oncogene 6: 1699-7103, 1991.
22. Slater SD, McGrath JA, Hobbs C, Eady RAJ, McKee PH: Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bellusa. Histopathology 20: 237-241, 1992.
23. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Mertinez JC, Martinez P: p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166: 235-241, 1992.
24. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G: p53 immunoreactivity in inflammatory and neoplastic disease of the uterine cervix. J Pathol 169: 425-430, 1993.
25. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GS, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
26. Crowell PL, Lemke SJ, Beckmann RP, Moore RE: Inhibition of human colon tumor cell proliferation by antisense oligonucleotides to mutant p53. Proc Annu Meet Am Assoc Cancer Res 34: A2951, 1993.
27. Borresen AL, Helland A, Nesland J, Holm R, Trope C, Kaern J: Papillomavirus, p53 and cervical cancer (Letter). Lancet 339: 1350-1351, 1992.
28. Raff MC: Social controls on cell survival and cell death. Nature 356: 397-400, 1992.
29. Lennon SV, Martin SJ, Cotter TG: Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 24: 203-214, 1991.
30. Dive C, Hickman JA: Durg-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192-196, 1991.
31. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E: The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins. Proc Natl Acad Sci USA 89: 7742-7746, 1992.
32. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128, 1992.
33. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
34. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus mediated transfer of the wild type p53 gene. Cancer Res 54: 2287-2291, 1994.
35. Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA, Miller DS, Mathis M: Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 59: 171-178, 1995.
36. Berchuck A, Bast RC Jr: Editorial. p53-based gene therapy of ovarian cancer: magic buller? Gynecol Oncol 59: 169-170, 1995.